Citius Pharmaceuticals (CTXR)
(Delayed Data from NSDQ)
$0.85 USD
+0.06 (7.63%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $0.85 0.00 (-0.26%) 6:34 PM ET
3-Hold of 5 3
D Value B Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CTXR 0.85 +0.06(7.63%)
Will CTXR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CTXR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CTXR
After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR)
CTXR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CTXR
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates
Sidoti Events, LLC's Virtual June Small-Cap Conference
Buy Rating Reaffirmed for Citius Pharmaceuticals Amid Strong Clinical Trial Results and Growth Prospects
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Biotech Alert: Searches spiking for these stocks today